Zydus Cadila

Synopsis- The ZY19489 is a novel antimalarial compound active against all current clinical strains of malaria-causing microorganisms ‘P. falciparum’ and ‘P. vivax’,…

Synopsis- Zydus announced today that it has received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor “ZYIL1”…

Synopsis – The company’s subsidiary has received tentative approval from the US Food and Drug Administration (USFDA) for Cariprazine capsules in the…